Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT
NCT ID: NCT01286675
Last Updated: 2019-03-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
19 participants
INTERVENTIONAL
2011-03-31
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma
NCT01484314
Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia
NCT01286038
Eltrombopag for Post Transplant Thrombocytopenia
NCT01000051
A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia
NCT02093325
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
NCT01491594
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Eltrombopag
0 mg Eltrombopag
Eltrombopag
oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Eltrombopag
oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Stable or responsive disease after at least 2 cycles of conventional chemotherapy
* Slated to undergo autologous peripheral blood stem cell transplant
* Normal organ and marrow function
Exclusion Criteria
* Receiving other study agents
* Pregnant or breastfeeding
* Uncontrolled intercurrent illness
* Evidence of active or recent history of thromboembolic disease
* Previous history of primary platelet disorder or bleeding disorder
* History of a different malignancy unless disease free for at least 5 years
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dana-Farber Cancer Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nancy Berliner, MD
Chief, Division of Hematology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nancy Berliner, MD
Role: PRINCIPAL_INVESTIGATOR
Dana-Farber Cancer Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-346
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.